Reuters logo
BRIEF-Ascendis Pharma says initiated regulatory submissions in Australia for entry into human clinical study with transcon parathyroid hormone
June 26, 2017 / 8:40 PM / 3 months ago

BRIEF-Ascendis Pharma says initiated regulatory submissions in Australia for entry into human clinical study with transcon parathyroid hormone

June 26 (Reuters) - Ascendis Pharma A/S

* Ascendis Pharma - initiated regulatory submissions in australia to enable co’s entry into its first human clinical study with transcon parathyroid hormone Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below